Clinical Research Directory

Inclusion Criteria: 1. Aged ≥ 18 years old; 2. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1, expected survival ≥ 3 months; 3. Histologically confirmed B-NHL; 4. Participant population: Have received ≥ 1 line of standard anti-tumor treatment, and have not achieved response after the latest treatment or have progressive disease after the treatment; 5. Have measurable lesions; 6. Have adequate organ function; 7. Male participants and female participants of childbearing potential must use adequate and effective contraceptive measures during the study and within 3 months after the last drug administration of SHR-3079. Female participants must not be lactating and must have a negative blood HCG test result within 7 days before the first dose; 8. Voluntarily sign the ICF, have good compliance, and be willing to cooperate with follow-up. Exclusion Criteria: 1. Central nervous system (CNS) infiltration; 2. Prior chemotherapy or other anti-lymphoma agents administered within 4 weeks before the first dose of study treatment; 3. Major surgery within 4 weeks before signing the ICF, or plan to undergo major surgery during the study period; 4. Receipt of CAR-T therapy or autologous stem cell transplant within 12 weeks prior to enrollment; 5. Receipt of allogeneic hematopoietic stem cell transplantation; 6. Prior solid organ transplantation; 7. Positive hepatitis C virus (HCV) antibody with HCV-RNA copy number above the upper limit of normal of the study site; positive hepatitis B surface antigen \[HBsAg\] and/or positive hepatitis B core antibody (HBcAb) with HBV DNA copy number above the upper limit of normal of the study site; 8. Presence of severe disorders involving major organ systems; 9. Pleural effusion, pericardial effusion, or ascites requiring frequent drainage or medical intervention; 10. Pregnant, lactating women, or women planning to become pregnant; 11. Have other serious physical or mental illness, laboratory test abnormalities, or other factors that may increase the risk of study participation or interfere with the study results.